Carcinoma, Non-Small-Cell Lung × Other solid neoplasm × Clear all
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

Phase 1/2 Recruiting
242 enrolled
NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
72 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT05461430 2025-09-15

TraveraRTGx

Travera Inc

Recruiting
200 enrolled
NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

Phase 1 Recruiting
345 enrolled
NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
NCT05563272 2025-07-10

STARBURST

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 2 Terminated
11 enrolled
NCT02349412 2025-02-07

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

Alliance for Clinical Trials in Oncology

Phase 3 Completed
405 enrolled 11 charts
NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 1 FDA
NCT04234113 2025-01-08

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Sotio Biotech Inc.

Phase 1 Terminated
115 enrolled
NCT05500508 2024-12-24

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Aminex Therapeutics, Inc.

Phase 1/2 Terminated
15 enrolled
NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
NCT06034860 2024-11-01

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Molecular Templates, Inc.

Phase 1 Terminated
15 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 1/2 Active not recruiting
179 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
71 enrolled
NCT04670445 2023-10-23

UPLIFT

Massachusetts General Hospital

Phase NA Unknown
210 enrolled
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled